PT  - JOURNAL ARTICLE
AU  - Serrallach, B.L.
AU  - Schafer, E.S.
AU  - Kralik, S.K.
AU  - Tran, B.H.
AU  - Huisman, T.A.G.M.
AU  - Wright, J.N.
AU  - Morgan, L.A.
AU  - Desai, N.K.
TI  - Imaging Findings in Children Presenting with CNS Nelarabine Toxicity
AID  - 10.3174/ajnr.A7692
DP  - 2022 Dec 01
TA  - American Journal of Neuroradiology
PG  - 1802--1809
VI  - 43
IP  - 12
4099  - http://www.ajnr.org/content/43/12/1802.short
4100  - http://www.ajnr.org/content/43/12/1802.full
SO  - Am. J. Neuroradiol.2022 Dec 01; 43
AB  - SUMMARY: Nelarabine is a nucleoside analog critical for the treatment of patients with T-cell acute lymphoblastic leukemia/lymphoma. However, clinical peripheral and central neurologic adverse events associated with nelarabine administration have been reported. Neuroimaging of brain neurotoxicity has only been described in very few reports in pediatric patients so far. Six children with diagnosed T-cell acute lymphoblastic leukemia who clinically experienced possible, probable, or definite nelarabine-induced toxicity and underwent spine and/or brain MR imaging were reviewed. Neuroimaging findings showed a mixture of patterns including features of acute toxic leukoencephalopathy (seen in 6 cases), posterior reversible encephalopathy syndrome (2 cases), involvement of deep gray structures (1 case) and brainstem (2 cases), cranial and spinal neuropathy (2 cases each), and myelopathy (2 cases). Even though neuroimaging findings are nonspecific, the goal of this article was to alert the pediatric neuroradiologists, radiologists, and clinicians about the possibility of nelarabine-induced neurotoxicity and its broad neuroimaging spectrum.aBFMaugmented Berlin-Frankfurt-MünsterAEadverse eventATLacute toxic leukoencephalopathyPApost (after) nelarabine administrationPRESposterior reversible encephalopathy syndromeT-ALLT-cell acute lymphoblastic leukemiaT1+Ccontrast-enhanced T1WI